Abstract
Symptom-based tuberculosis screening identifies less than one-third of eligible HIV-infected patients as candidates for isoniazid preventive therapy (IPT). We evaluated whether testing for C-reactive protein (CRP) improves patient selection for IPT. We measured CRP levels (normal <10 mg/L) using a point-of-care (POC) assay on stored serum samples from HIV-infected Ugandan adults initiating antiretroviral therapy. We assessed diagnostic accuracy in reference to baseline tuberculosis status adjudicated by an expert committee and calculated net reclassification improvement to quantify the incremental discriminatory benefit of POC-CRP in determining IPT eligibility compared to the World Health Organization (WHO) symptom screen. Of 201 patients (median CD4 cell count, 137 cells/μL; interquartile range, 83-206), 5 (2.5%) had tuberculosis. Compared to the WHO symptom screen, POC-CRP had similar sensitivity (100% vs. 80%, P = 0.30) but greater specificity (21% vs. 87%, P < 0.0001) for tuberculosis. If based on the WHO symptom screen, no patients with tuberculosis but only 42 of 196 patients without tuberculosis would have been considered IPT eligible. If POC-CRP were used instead, 1 patient with tuberculosis (reclassification of cases,...Continue Reading
References
Nov 25, 1981·Clinica Chimica Acta; International Journal of Clinical Chemistry·B ShineM B Pepys
Mar 31, 2001·Transactions of the Royal Society of Tropical Medicine and Hygiene·S D LawnR B Lal
Jan 7, 2003·Annals of Internal Medicine·Patrick M BossuytUNKNOWN Standards for Reporting of Diagnostic Accuracy
Jun 12, 2003·The European Respiratory Journal·A PolzinH Lode
Apr 2, 2005·The European Respiratory Journal·G K SchleicherC Feldman
Dec 2, 2009·The Korean Journal of Internal Medicine·Young Ae KangChoon-Taek Lee
Apr 10, 2010·International Journal of STD & AIDS·E K SageR F Miller
Apr 14, 2010·AIDS·Stephen D LawnRobin Wood
Jan 21, 2011·PloS One·Douglas WilsonGary Maartens
Jan 27, 2011·PLoS Medicine·Haileyesus GetahunJay K Varma
Aug 6, 2011·PLoS Medicine·Stephen D LawnRobin Wood
Sep 10, 2011·AIDS·Sheri D WeiserDavid R Bangsberg
Oct 22, 2011·The Lancet Infectious Diseases·Stephen D LawnRobin Wood
Feb 10, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Stephen D LawnRobin Wood
May 26, 2012·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Tendesayi KufaCeline R Gounder
Jun 14, 2012·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Sheri D WeiserDavid R Bangsberg
Apr 12, 2013·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·S D LawnR Wood
Citations
Apr 2, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Rupak ShivakotiUNKNOWN New Work Concept Sheet 319 and The Prospective Evaluation of Antiretrovirals in Resource-Limited Settings Study Team
Oct 7, 2016·AIDS Research and Therapy·Narendran GopalanSrikanth Tripathy
Mar 4, 2015·Open Forum Infectious Diseases·T T BalchaP Björkman
May 31, 2018·AIDS·Adrienne E ShapiroPaul K Drain
Nov 22, 2018·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jayant V RajanAdithya Cattamanchi
Jan 17, 2019·AIDS·Lelia H ChaissonChristina Yoon
Oct 29, 2019·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Fred C SemitalaChristina Yoon
Oct 24, 2018·PloS One·Katherine FarrAdithya Cattamanchi
Nov 27, 2018·Open Forum Infectious Diseases·Douglas WilsonGary Maartens
Apr 26, 2017·BMC Infectious Diseases·Monde MuyoyetaHelen Ayles
Dec 2, 2015·The Journal of Infectious Diseases·Rupak ShivakotiUNKNOWN NWCS 319 and PEARLS Study Team
Apr 1, 2020·Indian Journal of Clinical Biochemistry : IJCB·Bineeta KashyapN P Singh
Mar 17, 2021·Expert Review of Anti-infective Therapy·Lara FusaniLuisa Galli
Apr 13, 2021·EClinicalMedicine·Flora Martinez Figueira MoreiraJason R Andrews